SCHEMBL22216413

SCHEMBL22216413

CCOC(=O)C1C(=O)CCN(C(C)(C)CC)C1=O

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
GAA P10253 3/20 0.38
PKM P14618 2/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 2/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
ALDH1A1 P00352 4/20 0.36
POLB P06746 1/20 0.36
FKBP1A P62942 2/20 0.36
TLR4 O00206 1/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
KDM4E B2RXH2 2/20 0.35
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
HSP90AA1 P07900 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23907332 0.88 MAPT (0.51) MAPTGAAPKMHTTHSD17B10
SCHEMBL22207029 0.87 MAPT (0.50) MAPTGAAPKMHTTHSD17B10
SCHEMBL22216178 0.78 MAPT (0.52) MAPTGAAPKMHTTHSD17B10
SCHEMBL1303947 0.77 ALDH1A1 (0.39) MAPTGAAHTTHSD17B10ALDH1A1
SCHEMBL22216464 0.77 MAPT (0.40) MAPTGAAPKMHTTHSD17B10
SCHEMBL22338336 0.76 MAPT (0.39) MAPTGAAPKMHTTHSD17B10
SCHEMBL22323036 0.76 MAPT (0.39) MAPTGAAPKMHTTHSD17B10
SCHEMBL3367604 0.76 ALDH1A1 (0.39) MAPTGAAPKMHSD17B10ALDH1A1
SCHEMBL22207271 0.74 MAPT (0.37) MAPTGAAHSD17B10TSHRALDH1A1
SCHEMBL22323003 0.74 ALDH1A1 (0.40) MAPTPKMALDH1A1POLBTLR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371432-B2 Haloallylamine compounds and application thereof TRANSTHERA SCIENCES (NANJING), INC. (CN) 2025-07-29 US disclosed
EP-3892621-B1 HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF TRANSTHERA SCIENCES NANJING INC (CN) 2024-09-18 EP disclosed
US-20220081439-A1 HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF TransThera Sciences (Nanjing), Inc (CN) 2022-03-17 US disclosed
EP-3892621-A1 HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-10-13 EP disclosed
EP-3892621-A1 HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-10-13 EP disclosed
WO-2020143763-A1 HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF 南京药捷安康生物科技有限公司 2020-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371432-B2 Haloallylamine compounds and application thereof ADRA1D, ADRA1A, VAPA MAPT 398/4885GAA 2675/4885PKM 2499/4885
US-20220081439-A1 HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF ADRA1D, ADRA1A, VAPA MAPT 398/4885GAA 2675/4885PKM 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.